cytosine has been researched along with Uterine Cervical Neoplasms in 25 studies
Uterine Cervical Neoplasms: Tumors or cancer of the UTERINE CERVIX.
| Excerpt | Relevance | Reference |
|---|---|---|
| "This phase I trial aimed to assess the safety and determine the recommended Phase II dose (RP2D) of Cidofovir combined with chemoradiotherapy in patients with stage IB2-IVA cervical cancer." | 2.82 | Phase I trial evaluating the antiviral agent Cidofovir in combination with chemoradiation in cervical cancer patients. ( Adam, J; Bayar, MA; Chargari, C; Deutsch, E; Haie-Meder, C; Lanoy, E; Laporte, M; Levy, A; Magné, N; Mazeron, R; Mondini, M; Pautier, P; Soria, JC; Varga, A; Vassal, G, 2016) |
| "Hydralazine was administered to cohorts of 4 patients at the following dose levels: I) 50 mg/day, II) 75 mg/day, III) 100 mg/day and IV) 150 mg/day." | 2.71 | A phase I study of hydralazine to demethylate and reactivate the expression of tumor suppressor genes. ( Angeles, E; Cabrera, G; Cetina, L; Chanona-Vilchis, J; Chavez-Blanco, A; Duenas-González, A; Perez-Cardenas, E; Revilla-Vazquez, A; Sandoval, K; Segura-Pacheco, B; Taja-Chayeb, L; Trejo-Becerril, C; Zambrano, P, 2005) |
| "The GSE90627 dataset related to cervical cancer RKI was obtained from the Gene Expression Omnibus (GEO) database." | 1.91 | Cytosine-phosphate-guanine oligodeoxynucleotides alleviate radiation-induced kidney injury in cervical cancer by inhibiting DNA damage and oxidative stress through blockade of PARP1/XRCC1 axis. ( Chen, Y; He, Z; Zhang, D; Zhang, S, 2023) |
| " Our study suggests that inkjet printing technology can be utilized in the development of antiviral/anticancer combination dosage forms for mucosal application." | 1.46 | Inkjet printing of antiviral PCL nanoparticles and anticancer cyclodextrin inclusion complexes on bioadhesive film for cervical administration. ( Aktaş, Y; Bilensoy, E; Sandler, N; Varan, C; Wickström, H, 2017) |
| "Human papillomavirus (HPV) causes cervical cancer and a large fraction of head and neck squamous cell carcinomas (HNSCC)." | 1.43 | Cidofovir is active against human papillomavirus positive and negative head and neck and cervical tumor cells by causing DNA damage as one of its working mechanisms. ( Andrei, G; Mertens, B; Naesens, L; Nogueira, T; Snoeck, R; Stranska, R, 2016) |
| "Nearly all cervical cancers are associated with the high-risk subtypes of human papillomavirus (HPV) expressing the E6 and E7 oncoproteins." | 1.33 | Enhanced antiproliferative effects of alkoxyalkyl esters of cidofovir in human cervical cancer cells in vitro. ( Aldern, KA; Beadle, JR; Corbeil, J; Hostetler, KY; Rought, S; Trahan, J, 2006) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (12.00) | 18.2507 |
| 2000's | 9 (36.00) | 29.6817 |
| 2010's | 12 (48.00) | 24.3611 |
| 2020's | 1 (4.00) | 2.80 |
| Authors | Studies |
|---|---|
| Zhang, D | 1 |
| Zhang, S | 1 |
| He, Z | 1 |
| Chen, Y | 1 |
| Çelik-Uzuner, S | 1 |
| Varan, C | 1 |
| Wickström, H | 1 |
| Sandler, N | 1 |
| Aktaş, Y | 1 |
| Bilensoy, E | 1 |
| Deberne, M | 1 |
| Levy, A | 2 |
| Mondini, M | 2 |
| Dessen, P | 1 |
| Vivet, S | 1 |
| Supiramaniam, A | 1 |
| Vozenin, MC | 1 |
| Deutsch, E | 3 |
| De Schutter, T | 3 |
| Andrei, G | 5 |
| Topalis, D | 3 |
| Duraffour, S | 2 |
| Mitera, T | 2 |
| van den Oord, J | 2 |
| Matthys, P | 2 |
| Snoeck, R | 8 |
| Milutin Gašperov, N | 1 |
| Sabol, I | 1 |
| Planinić, P | 1 |
| Grubišić, G | 1 |
| Fistonić, I | 1 |
| Ćorušić, A | 1 |
| Grce, M | 1 |
| Nogueira, TC | 1 |
| El Amri, C | 1 |
| Krečmerová, M | 1 |
| Naesens, L | 3 |
| Balzarini, J | 1 |
| Haie-Meder, C | 1 |
| Bayar, MA | 1 |
| Laporte, M | 1 |
| Mazeron, R | 1 |
| Adam, J | 1 |
| Varga, A | 1 |
| Vassal, G | 1 |
| Magné, N | 1 |
| Chargari, C | 1 |
| Lanoy, E | 1 |
| Pautier, P | 1 |
| Soria, JC | 1 |
| Mertens, B | 1 |
| Nogueira, T | 1 |
| Stranska, R | 1 |
| Catalani, S | 1 |
| Palma, F | 1 |
| Battistelli, S | 1 |
| Nuvoli, B | 1 |
| Galati, R | 1 |
| Benedetti, S | 1 |
| Donne, AJ | 1 |
| Hampson, L | 1 |
| He, XT | 1 |
| Rothera, MP | 1 |
| Homer, JJ | 1 |
| Hampson, IN | 1 |
| Van Pachterbeke, C | 1 |
| Bucella, D | 1 |
| Rozenberg, S | 1 |
| Manigart, Y | 1 |
| Gilles, C | 1 |
| Larsimont, D | 1 |
| Vanden Houte, K | 1 |
| Reynders, M | 1 |
| Bossens, M | 2 |
| Yang, Y | 1 |
| Zhao, X | 1 |
| Chen, W | 1 |
| Gao, Z | 1 |
| Liu, A | 1 |
| Guo, J | 1 |
| Yan, Z | 1 |
| Dou, Y | 1 |
| Wang, H | 1 |
| Li, Y | 1 |
| Kašnar-Šamprec, J | 1 |
| Ratkaj, I | 1 |
| Mišković, K | 1 |
| Pavlak, M | 1 |
| Baus-Lončar, M | 1 |
| Kraljević Pavelić, S | 1 |
| Glavaš-Obrovac, L | 1 |
| Žinić, B | 1 |
| Ivanova, T | 1 |
| Vinokurova, S | 1 |
| Petrenko, A | 1 |
| Eshilev, E | 1 |
| Solovyova, N | 1 |
| Kisseljov, F | 1 |
| Kisseljova, N | 1 |
| Zambrano, P | 1 |
| Segura-Pacheco, B | 1 |
| Perez-Cardenas, E | 1 |
| Cetina, L | 1 |
| Revilla-Vazquez, A | 1 |
| Taja-Chayeb, L | 1 |
| Chavez-Blanco, A | 1 |
| Angeles, E | 1 |
| Cabrera, G | 1 |
| Sandoval, K | 1 |
| Trejo-Becerril, C | 1 |
| Chanona-Vilchis, J | 1 |
| Duenas-González, A | 1 |
| Hostetler, KY | 1 |
| Rought, S | 1 |
| Aldern, KA | 1 |
| Trahan, J | 1 |
| Beadle, JR | 1 |
| Corbeil, J | 1 |
| Amine, A | 1 |
| Vozenin-Brotons, MC | 1 |
| Abdulkarim, B | 2 |
| Violot, D | 1 |
| Aubel, C | 1 |
| Bourhis, J | 2 |
| Piette, J | 1 |
| Delvenne, P | 1 |
| De Clercq, E | 2 |
| Majeed, GS | 1 |
| Glew, S | 1 |
| Bidwell, J | 1 |
| Foksinski, M | 1 |
| Jaruga, P | 1 |
| Makarewicz, R | 1 |
| Olinski, R | 1 |
| Noel, JC | 1 |
| Muller, C | 1 |
| Sabri, S | 1 |
| Chagraoui, H | 1 |
| Maggiorella, L | 1 |
| Thierry, J | 1 |
| Eschwege, F | 1 |
| Vainchenker, W | 1 |
| Chouaïb, S | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| TOPical Imiquimod Treatment of High-grade Cervical Intraepithelial Neoplasm: a Randomized Controlled Trial.[NCT02329171] | Phase 3 | 9 participants (Actual) | Interventional | 2014-12-31 | Terminated (stopped due to Insufficient number of participants.) | ||
| "Phase III Clinical Trial: Evaluation of the Combination of TRANSKRIP ® Plus Carboplatin and Paclitaxel as First Line Chemotherapy on Survival of Patients With Recurrent - Persistent Cervical Cancer"[NCT02446652] | Phase 3 | 230 participants (Anticipated) | Interventional | 2015-07-31 | Not yet recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for cytosine and Uterine Cervical Neoplasms
| Article | Year |
|---|---|
Papillomavirus and treatment.
Topics: Antiviral Agents; Carcinoma; Chemotherapy, Adjuvant; Cidofovir; Cytosine; Female; Humans; Organophos | 2006 |
4 trials available for cytosine and Uterine Cervical Neoplasms
| Article | Year |
|---|---|
Phase I trial evaluating the antiviral agent Cidofovir in combination with chemoradiation in cervical cancer patients.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Antiviral Agents; Brachytherapy; Carboplatin; | 2016 |
Topical treatment of CIN 2+ by cidofovir: results of a phase II, double-blind, prospective, placebo-controlled study.
Topics: Administration, Topical; Adult; Antineoplastic Agents; Cidofovir; Combined Modality Therapy; Conizat | 2009 |
A phase I study of hydralazine to demethylate and reactivate the expression of tumor suppressor genes.
Topics: 5-Methylcytosine; Adult; Aged; Binding Sites; Biopsy; Cardiovascular Diseases; Cohort Studies; Cytos | 2005 |
Cidofovir, a new approach for the treatment of cervix intraepithelial neoplasia grade III (CIN III).
Topics: Adult; Antiviral Agents; Biopsy; Cervix Uteri; Cidofovir; Conization; Cytosine; Female; Humans; Immu | 2000 |
20 other studies available for cytosine and Uterine Cervical Neoplasms
| Article | Year |
|---|---|
Cytosine-phosphate-guanine oligodeoxynucleotides alleviate radiation-induced kidney injury in cervical cancer by inhibiting DNA damage and oxidative stress through blockade of PARP1/XRCC1 axis.
Topics: Animals; Creatinine; Cytosine; DNA Damage; Female; Guanine; Humans; Kidney; Mice; Mice, Inbred C57BL | 2023 |
Enhanced immunological detection of epigenetic modifications of DNA in healthy and cancerous cells by fluorescence microscopy.
Topics: Animals; Cell Line, Tumor; Cytosine; DNA; DNA Methylation; Female; Fluorescent Antibody Technique; H | 2019 |
Inkjet printing of antiviral PCL nanoparticles and anticancer cyclodextrin inclusion complexes on bioadhesive film for cervical administration.
Topics: Adenocarcinoma; Administration, Intravaginal; Antiviral Agents; Cell Line, Tumor; Cervix Uteri; Cido | 2017 |
The combination of the antiviral agent cidofovir and anti-EGFR antibody cetuximab exerts an antiproliferative effect on HPV-positive cervical cancer cell lines' in-vitro and in-vivo xenografts.
Topics: Animals; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antiviral Agents; Cell Cycle; Cel | 2013 |
Reduced tumorigenicity and pathogenicity of cervical carcinoma SiHa cells selected for resistance to cidofovir.
Topics: Animals; Antineoplastic Agents; Antiviral Agents; Apoptosis; Cell Line, Tumor; Cidofovir; Cytosine; | 2013 |
Methylated Host Cell Gene Promoters and Human Papillomavirus Type 16 and 18 Predicting Cervical Lesions and Cancer.
Topics: Adult; Biomarkers; Cell Line; Cervix Uteri; CpG Islands; Cytosine; DNA Methylation; DNA, Viral; Fema | 2015 |
Resistance to the nucleotide analogue cidofovir in HPV(+) cells: a multifactorial process involving UMP/CMP kinase 1.
Topics: ATP-Binding Cassette Transporters; Cell Line, Tumor; Cidofovir; Cytidine Triphosphate; Cytosine; Dru | 2016 |
Cidofovir is active against human papillomavirus positive and negative head and neck and cervical tumor cells by causing DNA damage as one of its working mechanisms.
Topics: Antiviral Agents; Carcinoma, Squamous Cell; Cell Line, Tumor; Cidofovir; Cytosine; DNA Damage; Femal | 2016 |
Reduced cell viability and apoptosis induction in human thyroid carcinoma and mesothelioma cells exposed to cidofovir.
Topics: Antineoplastic Agents; Antiviral Agents; Apoptosis; Cell Line, Tumor; Cell Survival; Cidofovir; Cyto | 2017 |
Cidofovir induces an increase in levels of low-risk and high-risk HPV E6.
Topics: Antiviral Agents; Cell Culture Techniques; Cidofovir; Cytosine; Female; Human papillomavirus 6; Huma | 2009 |
Effects of cidofovir on human papillomavirus-positive cervical cancer cells xenografts in nude mice.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cidofovir; Cytosine; Female; Humans; In Situ Nick-End Lab | 2010 |
In vivo toxicity study of N-1-sulfonylcytosine derivatives and their mechanisms of action in cervical carcinoma cell line.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Proliferation; Cells, Cultured; Cy | 2012 |
Cidofovir treatment improves the pathology caused by the growth of human papillomavirus-positive cervical carcinoma xenografts in athymic nude mice.
Topics: Animals; Antineoplastic Agents; Brain; Cachexia; Carcinoma; Cell Line, Tumor; Cidofovir; Cytokines; | 2013 |
Frequent hypermethylation of 5' flanking region of TIMP-2 gene in cervical cancer.
Topics: Alleles; Cell Line, Tumor; CpG Islands; Cytosine; DNA; DNA Methylation; Female; HeLa Cells; Humans; | 2004 |
Enhanced antiproliferative effects of alkoxyalkyl esters of cidofovir in human cervical cancer cells in vitro.
Topics: Antineoplastic Agents; Cell Proliferation; Cidofovir; Cytosine; Drug Screening Assays, Antitumor; Es | 2006 |
Cidofovir administered with radiation displays an antiangiogenic effect mediated by E6 inhibition and subsequent TP53-dependent VEGF repression in HPV18+ cell lines.
Topics: Angiogenic Proteins; Antineoplastic Agents; Cell Line, Tumor; Cidofovir; Cytosine; Down-Regulation; | 2006 |
Inhibiting effects of cidofovir (HPMPC) on the growth of the human cervical carcinoma (SiHa) xenografts in athymic nude mice.
Topics: Animals; Antineoplastic Agents; Antiviral Agents; Cidofovir; Cytosine; Dose-Response Relationship, D | 1998 |
An association between LSIL and the high secretor phenotype of IL-1beta.
Topics: Adenocarcinoma; Carcinoma in Situ; Carcinoma, Squamous Cell; Cytosine; Female; Humans; Interleukin-1 | 1999 |
Oxidative DNA base damage in cancerous tissues of patients undergoing brachytherapy.
Topics: Adenine; Brachytherapy; Cytosine; DNA Damage; DNA, Neoplasm; Female; Gas Chromatography-Mass Spectro | 1998 |
Antiviral agent Cidofovir restores p53 function and enhances the radiosensitivity in HPV-associated cancers.
Topics: Animals; Antiviral Agents; Carcinoma; Cell Division; Cidofovir; Cyclin A; Cyclin-Dependent Kinase In | 2002 |